Company / Total Assets
BridgeBio Pharma, Inc. Total Assets History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$936.0M
FY2025
5-year range
$546.4M / $1.0B
FY2021-FY2025
Trend
+1.8%
vs FY2024
Sector context
#87 of 214
Health Care
What the data says
At $936M, BridgeBio Pharma, Inc.'s total assets ranks #87 of 214 in the Health Care sector. Improved from $546M to $936M over the past 2 years.
Based on SEC 10-K filings.
$936M in FY2025 with a 5-year CAGR of +5.9%.
Improved from $546M to $936M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +14.5%
- 5-Year CAGR
- +5.9%
- 10-Year CAGR
- -
Sector benchmark
#87 of 214 in Health CareTop 41% of 214This company $936.0M Sector average $7.5B
▼
-87.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.9%, indicating consistent growth.
- In FY2025, total assets increased 1.8% year-over-year.
- Ranks #87 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $936.0M | +1.8% |
| FY2024 | $919.3M | +68.3% |
| FY2023 | $546.4M | -12.3% |
| FY2022 | $623.0M | -38.5% |
| FY2021 | $1.0B | +43.9% |
| FY2020 | $703.6M | +11.4% |
| FY2019 | $631.7M | +35.9% |
| FY2018 | $464.9M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026